Results 41 to 50 of about 3,367,821 (256)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders

F1000Research, 2018
JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as the driver mutation of the majority of non- BCR-ABL1 myeloproliferative neoplasms (MPNs).
W. Vainchenker, E. Leroy, L. Gilles, C. Marty, I. Plo, S. Constantinescu   +5 more
semanticscholar   +1 more source

Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

BMC Medical Genomics, 2019
Background Approximately 5–20% of chronic myeloid leukemia (CML) patients demonstrate primary resistance or intolerance to imatinib. None of the existing predictive scores gives a good prognosis of TKI efficacy.
Alexander V. Lavrov, Ekaterina Yu. Chelysheva, Elmira P. Adilgereeva, Oleg A. Shukhov, Svetlana A. Smirnikhina, Konstantin S. Kochergin-Nikitsky, Valentina D. Yakushina, Grigory A. Tsaur, Sergey V. Mordanov, Anna G. Turkina, Sergey I. Kutsev   +10 more
doaj   +1 more source

A rare case of late myelodysplasia cutis associated with essential thrombocythemia: A case report

SAGE Open Medical Case Reports, 2022
Myelodysplasia cutis is a relatively new described entity that is characterized by cutaneous plaques and nodules representing dermal infiltration of myeloid immature non-blastic cells.
Suzel Fournier, Sylvain Mailhot, Janie Bujold   +2 more
doaj   +1 more source

Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. [PDF]

, 2020
Mutation and translocation of fibroblast growth factor receptors often lead to aberrant signaling and cancer. This work focuses on the t(8;22)(p11;q11) chromosomal translocation which creates the breakpoint cluster region (BCR) fibroblast growth factor ...
Bisom-Rapp, Ezra W, Donoghue, Daniel J, Meyer, April N, Nelson, Katelyn N, Peiris, Malalage N   +4 more
core   +2 more sources

Failure of Splenectomy to Ameliorate Portal Hypertension in Myeloproliferative Disorders

Canadian Journal of Gastroenterology, 1994
The correct treatment of portal hypertension associated with myeloproliferative disorders remains uncertain. Splenectomy has been advocated by some to eliminate the forward flow component of the portal hypertension and thus reduce portal pressure.
Samuel S Lee, Guido Van Rosendaal, Thomas E Lay, James K Kelly, Graham F Pineo   +4 more
doaj   +1 more source

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia

Indian Journal of Medical and Paediatric Oncology, 2015
According to the 2008 revision of the World Health Organization (WHO) classification of myeloid malignancies, philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) include clonal, hematologic disorders such as polycythemia vera ...
M B Agarwal, Hemant Malhotra, Prantar Chakrabarti, Neelam Varma, Vikram Mathews, Jina Bhattacharyya, Tulika Seth, K Gayathri, Hari Menon, P G Subramanian, Ajay Sharma, Maitreyee Bhattacharyya, Jay Mehta, A K Vaid, Sandeep Shah, Shyam Aggarwal, P K Gogoi, Reena Nair, Usha Agarwal, Subhash Varma, S. V. S. S. Prasad, Marie Therese Manipadam   +21 more
doaj   +1 more source

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms [PDF]

, 2015
Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in JAK2, CALR or MPL, but the contribution of inherited factors is poorly characterized. Using a three-stage genome-wide association study of 3,437 MPN cases and 10,
Aranaz, P., Aranaz, P., Bandinelli, S., Bandinelli, S., Barosi, G., Barosi, G., Baxter, E.J., Baxter, E.J., Callaway, A., Callaway, A., Campbell P., Campbell P., Cazzola, M., Cazzola, M., Chase, A., Chase, A., Chen, E., Chen, E., Cross N.C., Cross N.C., Dohner, K., Dohner, K., Duncombe, A.S., Duncombe, A.S., Evans, P., Evans, P., Ewing, J., Ewing, J., Gale, R.E., Gale, R.E., Giannopoulos, A., Giannopoulos, A., Gisslinger, H., Gisslinger, H., Godfrey, A.L., Godfrey, A.L., Grallert, H., Grallert, H., Green, A.R., Green, A.R., Griffiths, M., Griffiths, M., Guglielmelli, P., Guglielmelli, P., Haferlach, T., Haferlach, T., Harrison, C., Harrison, C., Harutyunyan, A.S., Harutyunyan, A.S., Jack, A., Jack, A., Jones, A.V., Jones, A.V., Kralovics, R., Kralovics, R., Leung, W., Leung, W., Lin, F., Lin, F., Maclean, C., Maclean, C., Mannarelli, C., Mannarelli, C., Mead, A.J., Mead, A.J., Nangalia, J., Nangalia, J., Oscier, D., Oscier, D., Pieri, L., Pieri, L., Reiter, A., Reiter, A., Schnittger, S., Schnittger, S., Schuh, A., Schuh, A., Short, M., Short, M., Stegelmann, F., Stegelmann, F., Strauch, K., Strauch, K., Tanaka, T., Tanaka, T., Tapper, W., Tapper, W., Vannucchi, A., Vannucchi, A., Waghorn, K., Waghorn, K., Wallis, L., Wallis, L., Ward, D., Ward, D., White, H.E., White, H.E., Zoi, K., Zoi, K.   +99 more
core   +5 more sources

Differential Diagnoses of Systemic Mastocytosis in Routinely Processed Bone Marrow Biopsy Specimens: A Review [PDF]

, 2010
Diagnosis of systemic mastocytosis (SM) is mainly based on the morphological demonstration of compact mast cell infiltrates in various tissue sites. In almost all patients such infiltrates are detected in the bone marrow.
Horny, H. -P., Sotlar, K., Valent, P.
core   +1 more source

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation

Hematology, Transfusion and Cell Therapy, 2018
Background Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.
M. Cacemiro, J. Cominal, R. Tognon, N. Nunes, B. Simões, L. Figueiredo-Pontes, Luiz Fernando Bazzo Catto, F. Traina, E. Souto, Fabiana A. Zambuzi, F. Frantz, F. Castro   +11 more
semanticscholar   +1 more source

Markedly increased small-sized megakaryocytes and platelets count in the circulation with pseudo-hyperkalemia following splenectomy

European Journal of Medical Research, 2022
Megakaryocytes are common in the bone marrow and appear less often in circulation. Most studies on circulatory megakaryocytes have implicated myelodysplastic syndromes and myeloproliferative disorders because of disruption of the bone marrow barrier and ...
Guiying Li, Bin Wang, Dongyan Li, Rong Zhu, Xueyan Chen   +4 more
doaj   +1 more source